Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 7/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 5/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769479 | 0.91 | DRD3 (0.47) | DRD3DRD2HTR1ADRD4DRD1 | |
| SCHEMBL6773304 | 0.90 | DRD3 (0.46) | DRD3DRD2HTR2ADRD4HTR7 | |
| SCHEMBL6769511 | 0.90 | DRD3 (0.49) | DRD3DRD2HTR2AHTR1AHTR6 | |
| SCHEMBL6775115 | 0.90 | DRD3 (0.58) | DRD3HSD17B10DRD2HTR2AMEN1 | |
| SCHEMBL6776057 | 0.90 | DRD3 (0.50) | DRD3DRD2HTR2AHTR1ADRD1 | |
| SCHEMBL6775985 | 0.89 | DRD3 (0.46) | DRD3DRD2HTR2ADRD4HTR7 | |
| SCHEMBL6774919 | 0.84 | DRD2 (0.44) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6775473 | 0.84 | KCNH2 (0.50) | DRD3DRD2HTR1ADRD1 | |
| SCHEMBL6774334 | 0.83 | DRD3 (0.47) | DRD3DRD2HTR2AHTR1ADRD4 | |
| SCHEMBL6774076 | 0.83 | DRD3 (0.61) | DRD3HSD17B10DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020072515-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2002-06-13 | — | — | US | disclosed |
| EP-0807632-B1 | PYRROLOAZEPINE DERIVATIVES | SUNTORY LTD (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-6258805-B1 | TREATMENT OF BRAIN DISORDERS AND HYPERTENSION | SUNTORY LIMITED (JP) | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072515-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | DRD3 165/4885HSD17B10 2012/4885DRD2 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.